SandboxAQ, Deloitte Strengthen Partnership to Transform Healthcare - TECHx Media SandboxAQ, Deloitte Strengthen Partnership to Transform Healthcare
SandboxAQ has announced the expansion of its strategic alliance with Deloitte, bringing SandboxAQ's AI-driven LQM (Large Quantitative Models) simulation solutions to organizations globally. This collaboration aims to accelerate product development across various industries, particularly biopharma, leveraging both SandboxAQ's advanced AQBioSim and AQChemSim solutions, along with Deloitte's vast service capabilities in data and life sciences.
Andrew McLaughlin, Chief Operating Officer at SandboxAQ, expressed excitement over the expanded partnership, stating, 'AI simulation with Large Quantitative Models represents the next evolution of AI, transforming how organizations create value for their customers in ways that Large Language Models cannot.'
The integration of LQMs with Deloitte's Atlas AI™ knowledge graph will enable SandboxAQ's scientists to extract new, clinically relevant hypotheses, enhancing drug discovery processes. This collaboration combines Deloitte's engineering expertise and industry knowledge to streamline and accelerate drug discovery, utilizing AI-powered molecular simulations for deeper insights into drug development and treatment responses.
Aditya Kudumala, Principal at Deloitte Consulting LLP, emphasized the strength of the partnership, saying, 'Together, we aim to advance drug discovery and materials science for leading academic, commercial, and public sector entities.'
With this expanded alliance, the companies aim to drive innovation and efficiency in drug development, ultimately reshaping the healthcare and life sciences sectors.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
7 days ago
- Khaleej Times
Taxation Society hosts insightful conference on ‘UAE corporate tax evolution: The year 2 perspective'
The Taxation Society successfully hosted its flagship event, 'UAE corporate tax evolution: The year 2 perspective', on May 31 at India Club, Dubai. The full-day event attracted a diverse audience of tax professionals, business leaders, and finance experts, offering key insights into the UAE's fast-changing tax environment. The event commenced with opening remarks by Satish Kumar Sivan, consul-general of India to Dubai and Northern Emirates; and Tawhid Abdulla, chairman, Dubai Gold & Jewellery Group. Renowned speakers including Dinesh Khator, tax director, Deloitte Middle East; Jairajesh Nadar, senior manager, Deloitte UAE; Niraj Hutheesing, founder and MD, Cygnet One; Vijaya Mohan, managing partner, Evas Constantin Consultants; and Mithilesh Reddy, founder and CEO, SBC Tax Consulting, shared practical insights on corporate tax return filing, transfer pricing, e-invoicing and AI-driven compliance. A thought-provoking panel discussion on 'Navigating Change: The Evolving Role of Professionals in the UAE Corporate Tax Landscape' was moderated by Michael Armstrong, strategic adviser, ICAEW Middle East. The panel featured Zayd Khalid Maniar, managing partner, Crowe UAE; Stany Pereira, managing partner, PKF UAE; Hisham Farouk, CEO, Grant Thornton UAE; and Rakesh Pardasani, senior partner, RSM Dahman.
TECHx
03-06-2025
- TECHx
Vertiv Expands CoolChip CDU Line in EMEA Market
Home » Product Watch » Vertiv Expands CoolChip CDU Line in EMEA Market Vertiv (NYSE: VRT), a global provider of critical digital infrastructure, has announced the expansion of its Vertiv™ CoolChip CDU product line in the EMEA region. The launch includes three new models: Vertiv™ CoolChip CDU 70, CDU 100, and CDU 600. These direct-to-chip (DTC) liquid cooling solutions enhance Vertiv's position in the AI and high-performance computing (HPC) infrastructure space. The new models were revealed as part of Vertiv's commitment to scalable and efficient cooling for data centers. The company reported that the Vertiv CoolChip CDU 600 will debut in EMEA at the Datacloud Global Congress, taking place this week in Cannes. Sam Bainborough, vice president of EMEA thermal business at Vertiv, stated that rising workloads and higher rack densities are driving the demand for adaptable liquid cooling systems. He added that the CoolChip CDU line provides flexible and scalable solutions that reduce complexity and support future growth. The new CDUs are designed for both retrofit and greenfield data center environments. They include in-rack and row-based configurations with both liquid-to-air and liquid-to-liquid technologies. According to Vertiv, the expanded CoolChip family is part of its broader 360AI portfolio. This includes power, cooling, and services designed to tackle the challenges of AI deployments. The CDUs are also supported by Vertiv™ Liquid Cooling Services, which cover design, installation, fluid management, and maintenance. This allows for deployment in diverse scenarios, from existing facility upgrades to scaling dense AI and HPC clusters. Key product highlights include: CoolChip CDU 70 : An in-row, liquid-to-air CDU with 70 kW cooling capacity. It offers fast, cost-effective entry into liquid cooling with minimal infrastructure changes. : An in-row, liquid-to-air CDU with 70 kW cooling capacity. It offers fast, cost-effective entry into liquid cooling with minimal infrastructure changes. CoolChip CDU 100 : A liquid-to-liquid, in-rack unit delivering 100 kW cooling in a compact 4U design. It supports one-rack-at-a-time liquid cooling deployment. : A liquid-to-liquid, in-rack unit delivering 100 kW cooling in a compact 4U design. It supports one-rack-at-a-time liquid cooling deployment. CoolChip CDU 600: An in-row, liquid-to-liquid system providing 600 kW cooling. It targets high-density, hyperscale, and colocation environments with redundant pumps and advanced monitoring. Vertiv revealed that all models feature integrated controllers for real-time monitoring, group control, and efficient scaling. Built-in filtration and precise temperature control enhance fluid quality and operational stability. The company emphasized that the new systems simplify deployment and speed up the transition to liquid cooling across EMEA data centers.
Al Etihad
03-06-2025
- Al Etihad
M42, AstraZeneca, SOPHiA GENETICS to transform cancer diagnosis, care
3 June 2025 14:30 ABU DHABI (ALETIHAD)M42, a global health leader powered by technology, announced a strategic collaboration with AstraZeneca and SOPHiA GENETICS to bring cutting-edge liquid biopsy testing to the UAE, aimed at advancing cancer diagnosis, informing treatment decisions, and enabling faster, accurate biomarker testing across a broad range of part of the collaboration, M42 will integrate SOPHiA GENETICS' MSK-ACCESS®, powered with SOPHiA DDM™ technology, into its testing infrastructure, enabling non-invasive genomic profiling of cancers through a simple blood approach does not replace but rather complements routine cancer screenings, and is designed for patients who are unable to undergo a solid tumor biopsy, enabling them to be matched with a precision therapy tailored to their specific cancer the next 12 months, the partnership will enable liquid biopsy testing access across select leading hospitals across the UAE, providing patients with faster, less invasive biomarker insights compared to traditional tissue biopsies, while also strengthening testing infrastructure and capabilities for a wide range of cancers in the new testing programme will initially target lung, ovarian, breast, colorectal, and pancreatic cancers, among others, addressing some of the most critical cancer burdens in the studies are set to commence shortly at Cleveland Clinic Abu Dhabi, marking a key milestone toward the full clinical launch planned for the latter part of Q2 El-khani, Senior Vice President, Operations, Integrated Health Solutions at M42, said, 'This collaboration reflects our vision of democratising health by making advanced diagnostics accessible to more patients, supporting not just early diagnosis but also real-time treatment monitoring and cost-effective, precise, predictive, and personalised care.'Sameh El Fangary, Cluster President GCC of AstraZeneca, stated, "Our work, and our collaborations with partners across industry, are driving towards better treatments for patients as well as a more sustainable future for healthcare systems. Through our latest partnerships, we are committed to transforming cancer care for millions in the region by advancing early diagnosis and optimising patient pathways from detection to therapy.' Ross Muken, President of SOPHiA GENETICS, said, "Expanding access to advanced testing technologies is central to our mission at SOPHiA GENETICS. Partnering with M42 and AstraZeneca in the UAE allows us to equip healthcare providers with the tools they need to personalise care, monitor disease in real-time, and ultimately improve outcomes for patients across the region." Source: Aletihad - Abu Dhabi
